NEW YORK (GenomeWeb News) – Precision Antibody announced today it has been selected by SAIC-Frederick to supply antibody and antigen characterization for the National Cancer Institute's proteomics initiative.
Precision will assist SAIC-Frederick with the characterization of newly developed monoclonal antibodies, as well as antigens, as part of the NCI's Clinical Proteomic Technologies for Cancer program. The project will include surface plasmon resonance analysis.
Precision will perform full kinetic analyses of antigen-antibody interactions "by determining real-time on- and off-rates and affinity constants of selected antibody-antigen pairs," the company said in a statement. Other methods of characterizations also will be used, including ELISA, Western blot analyses, isotyping, and antigen characterization by SDS-PAGE, the company added.
Terms of the contract were not disclosed.
CPTC is a five-year, $104 million initiative created by the NCI in 2005 to explore how proteomics can be used in cancer research. One of the projects of the program is to develop a standardized resource of highly-characterized, high-quality reference antibodies generated against cancer-associated proteins.
The antibodies will be made available to the research community along with characterization data "intended to support replication and standardization," Precision said.
The contract is the second awarded to Precision under NCI's CPTC initiative, following a contract given in October to develop monoclonal antibodies for 20 cancer-related target proteins.